BOSTON, March 3 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. is pleased to announce that the Company has completed a Food and Drug Administration (FDA) Level II Baseline Inspection and received a NAI (No Action Indicated) for the inspection. It is standard for the FDA to periodically perform unannounced inspections for medical device manufacturers and the successful inspection by the FDA validates the Company's quality system and its strict adherence to that system.
Solos Endoscopy's surgical product line is currently being used by surgeons and medical technicians in hospitals and medical facilities across the country. Solos Endoscopy's MammoView(TM) was also recently featured in two surgical trade magazines, Surgical Products and Outpatient Surgery, which is reflective of its growing popularity with the medical community.
"Successful completion of the FDA Inspection also validates the hard work and dedication of our employees and their commitment to patient safety, as well as providing surgical instrumentation of the highest quality," stated Bob Segersten, President of Solos Endoscopy, Inc.
About Solos Endoscopy, Inc.:
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices and procedural techniques for the screening, diagnosis, treatment and management of medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: www.solosendoscopy.com.
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
CONTACT: Investor Relations for Solos Endoscopy, Inc., +1-866-843-2775
Web site: http://www.solosendoscopy.com/
